IHH Healthcare Brings IHH Catalyst to North Asia to Boost Clinical Innovation

In July 2026, IHH Healthcare introduced the IHH Catalyst North Asia Edition in collaboration with its subsidiaries, such as Gleneagles Hong Kong and Parkway Shanghai. The company has already introduced its IHH Catalyst program in India successfully and now intends to bring it to Hong Kong and China. This is the second edition of the initiative that aims to boost the adoption of patient-focused, advanced technology solutions in hospitals and clinics in these countries.

The first edition of this program was unveiled as the IHH Catalyst Fortis India Edition in February 2026, which integrated the ecosystem of healthcare entrepreneurs, clinicians, and operational experts to enhance reliable solutions from pilot stage to execution. Plug and Play is the program partner of IHH Catalyst as it helps global innovation healthcare startups in their development.

Gleneagles Hong Kong and Parkway Shanghai will contribute by providing the participating startups access to their multidisciplinary departments across their healthcare ecosystem in Hong Kong and China. According to Ashok Pandit, the Group Chief Corporate Officer at IHH Healthcare, Hong Kong and China have well-developed healthcare and technology sectors, with rapid growth in customized care, advanced medicine, cancer treatments, and extensive adoption of digital workflows.

According to Dr. Kenneth Tsang, the Regional CEO of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, healthcare is becoming more and more sophisticated and multi-disciplinary, which increases the need for the partnership of various disciplines, institutions, and sectors. IHH Catalyst North Asia Edition will provide access to healthcare expertise in Hong Kong and China to startups in North Asia to help them execute their research projects in the real world.

This initiative will concentrate on early-phase startups as well as late-stage research firms that have their projects ready for clinical testing and real-world execution. The selected startups will receive the following benefits:

• Guidance from IHH, Gleneagles Hong Kong and Parkway Shanghai experts and management.
• Opportunities to test and validate their pilot projects in an actual hospital ecosystem.
• Future Strategy guidance regarding long-term collaborations and scaling of workflows.

Impact on the Healthcare Industry

According to Precedence Research, the launch of IHH Catalyst North Asia Edition is expected to positively impact the healthcare industry as it promotes the development of healthcare facilities in countries where medical facilities are not able to serve patients optimally. It provides technology and infrastructure from Hong Kong and China to startups in North Asia to help them grow. This initiative will help the people in those countries receive better treatments.

Impact on the Healthcare Facilities Management Market

The global healthcare facilities management market size is calculated at USD 368.8 billion in 2025 and is predicted to increase from USD 417.6 billion in 2026 to approximately USD 889.6 billion by 2035, expanding at a CAGR of 9.2% from 2026 to 2035.

According to Precedence Research, the introduction of the IHH Catalyst North Asia Edition is expected to benefit the healthcare facilities management market. This is because the development of the healthcare sector in North Asia would require improvements in energy and medical infrastructure in the region. They would need advanced medical equipment, surgical devices, cold chain transport solutions, and a skilled medical workforce. This would create a significant demand for medical facilities management services to help these countries develop their healthcare ecosystem. This would be an important step in delivering effective and reliable medical treatment to the citizens of those nations.

Impact on the Healthcare Supply Chain Management Market

The global healthcare supply chain management market size is calculated at USD 3.95 billion in 2025 and is predicted to increase from USD 4.16 billion in 2026 to approximately USD 6.63 billion by 2035, expanding at a CAGR of 5.32% from 2026 to 2035.

According to Precedence Research, the healthcare supply chain market is expected to be positively impacted by the launch of the IHH Catalyst North Asia Edition. This is because those countries would need a robust supply chain to safely transport biologics, drugs, vaccines, surgical fluids, and organs for organ transplants. The demand for these services would increase as the healthcare startups implement their pilot projects in the real world. Supply chain is critical in the medical sector as medical fluids and equipment need to be transported at optimal temperature and securely packaged to avoid any spoilage and impurities.

About IHH Healthcare

IHH Healthcare is a prominent global private healthcare group that provides high-quality medical treatment to millions of patients across the globe. This group has 89 hospitals in 10 countries, and its key markets include Malaysia, Singapore, Türkiye and India. This group has a workforce of over 76,000 and provides a wide range of services, from primary services to quaternary services, as well as complementary ancillary services. The portfolio of this group consists of various reliable healthcare brands such as Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway.